Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin (TTY Biopharm Company Limited)
- Development stage
- Unknown
- Lead developer
- TTY Biopharm
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Lipo-Dox is a pegylated liposomal formulation of doxorubicin hydrochloride developed by TTY Biopharm. It utilizes 'Stealth' technology, where the active anthracycline agent is encapsulated within liposomes coated with polyethylene glycol (PEG). This modification significantly alters the drug's pharmacokinetic profile by extending its circulation half-life and allowing for preferential accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect. Doxorubicin itself acts by intercalating into DNA and inhibiting topoisomerase II, which prevents DNA replication and leads to apoptosis. The liposomal delivery system is designed to reduce systemic toxicities, particularly cardiotoxicity and alopecia, compared to conventional doxorubicin, although it is associated with specific adverse effects such as palmar-plantar erythrodysesthesia. Lipo-Dox is indicated for the treatment of metastatic breast cancer, advanced ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma.
- Brand names
- Lipo-Dox
- Other names
- pegylated liposomal doxorubicinliposomal doxorubicindoxorubicin hydrochloride liposome
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin (TTY Biopharm Company Limited).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin (TTY Biopharm Company Limited).